Equities research analysts at StockNews.com began coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Rating) in a note issued to investors on Friday. The brokerage set a “hold” rating on the stock.
Several other brokerages also recently weighed in on MEIP. Jefferies Financial Group downgraded MEI Pharma from a “hold” rating to an “underperform” rating in a research report on Wednesday, February 8th. Truist Financial downgraded MEI Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, December 6th. Piper Sandler downgraded MEI Pharma from an “overweight” rating to a “neutral” rating in a research report on Friday, February 24th. BTIG Research downgraded MEI Pharma from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 6th. Finally, HC Wainwright dropped their target price on MEI Pharma from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Monday, February 13th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $2.43.
MEI Pharma Stock Performance
NASDAQ:MEIP opened at $0.24 on Friday. The stock has a fifty day moving average price of $0.29 and a 200-day moving average price of $0.33. The company has a market cap of $31.98 million, a price-to-earnings ratio of -1.04 and a beta of 1.03. MEI Pharma has a fifty-two week low of $0.20 and a fifty-two week high of $1.94.
Hedge Funds Weigh In On MEI Pharma
Institutional investors have recently added to or reduced their stakes in the business. Carlson Capital L P lifted its stake in MEI Pharma by 4.5% in the third quarter. Carlson Capital L P now owns 1,150,000 shares of the company’s stock valued at $445,000 after buying an additional 50,000 shares during the period. Assenagon Asset Management S.A. acquired a new position in MEI Pharma in the third quarter valued at approximately $39,000. Laurion Capital Management LP acquired a new position in MEI Pharma in the second quarter valued at approximately $1,559,000. Sigma Planning Corp lifted its stake in MEI Pharma by 50.9% in the second quarter. Sigma Planning Corp now owns 632,200 shares of the company’s stock valued at $382,000 after buying an additional 213,250 shares during the period. Finally, Mirabella Financial Services LLP acquired a new position in MEI Pharma in the first quarter valued at approximately $76,000. 35.74% of the stock is owned by institutional investors and hedge funds.
About MEI Pharma
MEI Pharma, Inc is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its products include Zandelisib, Voruciclib, and ME-344. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
- Get a free copy of the StockNews.com research report on MEI Pharma (MEIP)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.